Compass pathways stock forecast.

Nov 29, 2023 · About CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.WebThe average Atai Life Sciences Nv stock price prediction forecasts a potential upside of 1,490.91% from the current ATAI share price of $1.10. What is ATAI's forecast return on equity (ROE) for 2023-2026? (NASDAQ: ATAI) forecast ROE …COMPASS Pathways has a market cap of $299.3 million, and a 52-week range of $6.74 to $49.52. The stock has a price/book ratio of 1.32, and a price-to-free-cash-flow ratio of -6.9.Web

Compass Pathways PLC. 5.94. Delayed Data. As of Nov 29. -0.04 / -0.67%. Today’s Change. 5.01. Today ||| 52-Week Range. 11.48.Find the latest COMPASS Pathways plc (CMPS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Current. -$0.61. 1 Month Ago. -$0.60. 3 Months Ago. -$0.65. COMPASS Pathways PLC ADR analyst estimates, including CMPS earnings per share estimates and analyst recommendations.Web

When a company is developing a novel therapy, sometimes good news takes an unusual form. For Compass Pathways, ( CMPS -8.84%) whose COMP360 program aims to address treatment-resistant depression ...

17 de out. de 2022 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.COMPASS Pathways is a market leader in the listed psychedelics space and the company has made significant advances over the last few years. COMPASS is burning through cash at a high rate relative ...16 de ago. de 2023 ... The psychedelics biotech firm is set to receive $125 million selling stocks upfront, with a potential addition of $160 million from ...Nov 29, 2023 · View COMPASS Pathways PLC Sponsored ADR CMPS investment & stock information. Get the latest COMPASS Pathways PLC Sponsored ADR CMPS detailed stock quotes, stock data, Real-Time ECN, charts, stats ... That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51% ...

COMPASS Pathways EBIT Forecast for 2023 - 2025 - 2030. In the last year, COMPASS Pathways's EBIT has grown from $-47.15M to $-73.57M – a 56.03% increase. For the following year, the 0 analysts predict that COMPASS Pathways's EBIT will drop by 35.91%, reaching $-47.15M. In 2030, the professionals' prediction is that CMPS's EBIT will decrease ...

On May 2, COMPASS Pathways (CMPS 6.61%) announced that the American Medical Association (AMA) ... This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock.

16 ส.ค. 2566 ... ... Price” requirement (as defined in the Nasdaq rules). COMPASS intends to use the net proceeds from the proposed financing to fund its pivotal ...Get a real-time COMPASS Pathways plc (CMPS) stock price quote with breaking news, financials, statistics, charts and more.COMPASS Pathways EBIT Forecast for 2023 - 2025 - 2030. In the last year, COMPASS Pathways's EBIT has grown from $-47.15M to $-73.57M – a 56.03% increase. For the following year, the 0 analysts predict that COMPASS Pathways's EBIT will drop by 35.91%, reaching $-47.15M. In 2030, the professionals' prediction is that CMPS's EBIT will decrease ... COMPASS Pathways (CMPS) Stock Forecast & Price Target $5.93 -0.05 (-0.84%) (As of 11/29/2023 ET) Compare Today's Range $5.84 $6.25 50-Day Range …17 de out. de 2022 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.2 พ.ย. 2566 ... Each share of common stock and accompanying common warrant to purchase one share of common stock are being sold at a combined price to the ...COMPASS Pathways (NASDAQ: CMPS) has seen its earnings outlook for FY2023 revised by Cantor Fitzgerald. The equities researchers at Cantor Fitzgerald have raised their EPS estimates, predicting that the company will now earn ($2.08) per share for the year, up from their previous forecast of ($2.24).

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.The current Compass Pathways PLC [ CMPS] share price is $6.10. The Score for CMPS is 44, which is 12% below its historic median score of 50, and infers higher risk than normal. CMPS is currently trading in the 40-50% percentile range relative to its historical Stock Score levels. The Compass Pathways Plc (CMPS) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $20.62, representing a +291.30% increase from the current price of $5.27. The highest analyst price target is $35.17, and the lowest is $6.0744. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. Insider Ownership Of COMPASS Pathways The definition of company insiders can be subjective and does vary ...Compass Pathways has also returned positive data from a Phase 2 trial of its psilocybin formulation, using a similar "monitored sessions" approach, even providing music, soft furnishings and a ...

The consensus 12-month price target for Compass Pathways reflects an upside potential of close to 325%. Even the most pessimistic analyst surveyed by Refinitiv thinks that the stock will double ...Web

On May 2, COMPASS Pathways (CMPS 6.61%) announced that the American Medical Association (AMA) ... This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock.Aug 26, 2023 · Beam Therapeutics (BEAM-1.72%), COMPASS Pathways (CMPS-6.05%), ... The average price target for the stock is $41.67, implying a 382% upside potential from its current share price. Like Beam ... Key Points. Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices. Wall Street analysts have ...Get Compass Pathways PLC (CMPS.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.COMPASS Pathways Stock forecast & analyst price target predictions based on 6 analysts offering 12-months price targets for 5Y6 in the last 3 months.About the COMPASS Pathways Plc stock forecast. As of 2023 November 27, Monday current price of CMPS stock is 6.450$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).COMPASS Pathways PLC Sponsored ADR (CMPS) Just Flashed Golden Cross Signal: Do You Buy? 09/08/23-8:55AM EST Zacks Pediatrix (MD) Down 4.2% Despite Q1 Earnings & Revenue Beat 05/05/23-11:16AM EST ZacksJul 2, 2023 · COMPASS Pathways is a mental healthcare company that specializes in psilocybin therapy. Read more to see my thoughts on CMPS stock and why it is a Hold. ... CMPS Stock Forecast. Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select ...18 ก.ย. 2563 ... That was up from initial expectations for $14-$16 announced earlier in the week, putting the valuation at about $544 million. Compass said it ...

BTIG analyst Robert Hazlett maintained a Buy rating on COMPASS Pathways (CMPS – Research Report) yesterday and set a price target of $47.0... BTIG analyst Robert Hazlett maintained a Buy rating on COMPASS Pathways (CMPS – Research Rep...

Fresh off IPO, Compass sees mushrooming opportunity in psilocybin....CMPS Psychedelic company Compass Pathways PLC (CMPS) got off to a stellar start of trading on Friday, as investors hungry for the next new thing bought up shares. The U.K....

May 13, 2022 · COMPASS Pathways has a market cap of $299.3 million, and a 52-week range of $6.74 to $49.52. The stock has a price/book ratio of 1.32, and a price-to-free-cash-flow ratio of -6.9. Nikkei 225. 30,696.96. -0.95%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Compass Pathways PLC (CMPS.OQ) real-time stock quotes, news, price and financial information from ...WebThe Compass Pathways Plc (CMPS) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $20.62, representing a +291.30% increase from the current price of $5.27. The highest analyst price target is $35.17, and the lowest is $6.0744.US20451W1018. Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom. Show more.A. While ratings are subjective and will change, the latest Compass Pathways ( CMPS) rating was a reiterated with a price target of $0.00 to $21.00. The current price Compass Pathways ( CMPS) is ...Last Friday, U.K.-based Compass Pathways (NASDAQ: CMPS) became the first psychedelic medicine company to go public on a major U.S. exchange. The drugmaker's shares promptly rose by an eye-catching ...We note that hedge funds don't have a meaningful investment in COMPASS Pathways. Atai Life Sciences N.V. is currently the company's largest shareholder with 19% of shares outstanding. The second ...According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 722.55%. The lowest target is $19 and the highest is $120. On average, analysts rate CMPS stock stock as a strong buy.

It may have a tough pill to swallow, but I'm still optimistic about psilocybin in general, and especially Cybin....CMPS At the time of publication, Tim Collins was long CYBN. Look how quickly we got bulled up. Let's check sentiment, the...Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Compass Pathways stock indicated to open around $25.00, or 47% above the $17 IPO price. Sep. 18, 2020 at 10:17 a.m. ET by Tomi Kilgore.Instagram:https://instagram. 6 months treasury yieldxqqrol stockhow to purchase stocks in canada Dec 26, 2020 · Despite having an IPO just three months ago, Compass Pathways ( CMPS -3.64%) is already up a staggering 224% from its IPO price of $17. If you invested $10,000 in its first-ever public offering ... insider trading stockbest audiobooks for investing Zacks forecast a loss of 55 cents per share. The company had zero revenue, as its main product, COMP360, is still in trials. ... Compass Pathways stock is in an IPO base with a 47.39 buy point. buy A buy now? Luckily, Compass Pathways stock doesn't have a rousing success for COMP360 already baked into its price. The company's market cap of $1.4 billion at the moment isn't terribly high for a ...COMPASS Pathways Stock forecast & analyst price target predictions based on 6 analysts offering 12-months price targets for 5Y6 in the last 3 months.markets.businessinsider.com - August 7 at 4:42 PM. HC Wainwright Reiterates "Buy" Rating for COMPASS Pathways (NASDAQ:CMPS) marketbeat.com - August 4 at 2:37 PM. Compass Pathways Plc (CMPS) Q2 2023 Earnings Call Transcript. finance.yahoo.com - August 4 at 4:00 AM. COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady …